Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Olodaterol/Tiotropium FDC vs Single Agents in COPD
NCT02231177Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of Olodaterol in plasma over the time interval from 0 to 1 hour at steady state, Maximum measured concentration of Olodaterol in plasma at steady state at Day 21 and 1 more. Started Jun 2008; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02231177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231177.